Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-40.95%
0%
-40.95%
6 Months
-94.22%
0%
-94.22%
1 Year
-95.14%
0%
-95.14%
2 Years
-98.68%
0%
-98.68%
3 Years
-98.95%
0%
-98.95%
4 Years
-99.74%
0%
-99.74%
5 Years
-99.88%
0%
-99.88%
PHAXIAM Therapeutics SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
9.94%
EBIT to Interest (avg)
-33.02
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.61
Sales to Capital Employed (avg)
0
Tax Ratio
6.22%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.13
EV to EBIT
-0.51
EV to EBITDA
-0.53
EV to Capital Employed
0.46
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-90.49%
ROE (Latest)
-131.73%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Jun 2023
Shareholding Compare (%holding) 
Majority shareholders
Non Institution
Domestic Funds
Held in 5 Schemes (0.7%)
Foreign Institutions
Held by 5 Foreign Institutions (3.22%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-23.80
-29.20
18.49%
Interest
0.20
1.40
-85.71%
Exceptional Items
0.40
-1.70
123.53%
Consolidate Net Profit
-23.50
-0.20
-11,650.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -11,650.00% vs 99.63% in Dec 2022
About PHAXIAM Therapeutics SA 
PHAXIAM Therapeutics SA
Pharmaceuticals & Biotechnology
Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The Company's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death.
Company Coordinates 
Company Details
Batiment Adenine 60 avenue Rockefeller , LYON None : 69008
Registrar Details






